VALENCIA, Spain and BRUSSELS, July 03, 2024 (GLOBE NEWSWIRE) -- Seeking alternatives to obtain oocytes without ovarian stimulation is a pioneering line of research in reproductive medicine. The inconveniences that the process of ovarian stimulation can generate are a current barrier for some women and couples who are considering starting a reproductive treatment.

巴伦西亚，西班牙和布鲁塞尔，2024年7月3日（环球通讯社）--寻找替代品以获得无卵巢刺激的卵母细胞是生殖医学研究的先驱。卵巢刺激过程可能产生的不便是目前一些正在考虑开始生殖治疗的女性和夫妇的障碍。

In fact, 1 out of every 5 couples do not start the search for a second child for this reason. Ovarian stimulation is the initial part of assisted reproduction treatments, and it is the phase of infertility treatments in which the least relevant advances have been achieved to date. It is one of the main psychological barriers for women when deciding to begin this path towards motherhood.

事实上，出于这个原因，每5对夫妇中就有1对没有开始寻找第二个孩子。卵巢刺激是辅助生殖治疗的最初部分，也是迄今为止取得最不相关进展的不孕症治疗阶段。。

Many of them are concerned about how this process may affect them physically and emotionally. With the aim of making progress in this field, IVI RMA GLOBAL has signed an exclusive agreement with Lavima Fertility, Inc., a US company in the fertility sector which owns the rights to CAPA-IVM, a completely novel hormone-free fertility treatment technology.

他们中的许多人担心这个过程会对他们的身体和情绪产生怎样的影响。为了在这一领域取得进展，IVI RMA GLOBAL与美国生育部门的一家公司Lavima Fertility，Inc.签署了独家协议，该公司拥有CAPA-IVM（一种全新的无激素生育治疗技术）的权利。

Together, IVI RMA Global and Lavima Fertility have opened a pioneering line of research aimed at eliminating ovarian stimulation in women who wish to begin assisted reproduction or egg vitrification treatment. 'We are aware that the ovarian stimulation phase can be faced with some anxiety and can be a brake on the decision to begin treatment.

IVI RMA Global和Lavima Fertility共同开创了一条开创性的研究路线，旨在消除希望开始辅助生殖或卵子玻璃化治疗的女性的卵巢刺激我们知道，卵巢刺激阶段可能会面临一些焦虑，可能会阻碍开始治疗的决定。

For this reason, at IVI and together with Lavima Fertility, we have taken the initiative and we are going to challenge science to try to optimize this very delicate part of the treatment for some patients,' explains Dr. Nuria Pellicer, gynecologist at IVI Valencia. A clinical study has begun at the IVI Valencia headquarters under the direct.

。一项临床研究已经在IVI巴伦西亚总部直接开始。